Alexa
  • Directory of Taiwan

Roche says its Tarceva pancreatic cancer treatment won European Union approval

Roche says its Tarceva pancreatic cancer treatment won European Union approval

Swiss pharmaceutical company Roche Holding AG said Monday that its Tarceva pancreatic cancer treatment won approval from the European Commission for use in combination with standard chemotherapy.
Pancreatic cancer has the highest one-year mortality rate of any cancer and is Europe's sixth-deadliest cancer, the company said.
"This is a much needed treatment advance for patients suffering with this difficult-to-treat disease," said William Burns, chief executive of Roche's pharmaceuticals unit.
In 2002, there were more than 78,000 new cases of pancreatic cancer diagnosed in Europe, with a death rate of approximately 82,000 people per year, Roche said.
Pancreatic cancer is difficult to treat as it is often resistant to chemotherapy and radiotherapy and tends to spread quickly to other parts of the body, leading to a short life expectancy.
Shares in Roche fell 0.3 percent to 232.30 Swiss francs (euro143.50; US$185.38) in Zurich trading.


Updated : 2021-05-13 13:54 GMT+08:00